Age-related macular degeneration is one of the leading causes of blindness worldwide in patients older than 60 years. Because of the aging population, it is of great importance to diagnose the disease early to help the patients get access to treatment. In its incipient stages, patients are usually asymptomatic, but the advanced disease can progress very fast, and it severely affects visual acuity. Over time there have been proposals for screening programs for patients with AMD, but at the moment there are no programs in most countries. The disease burden is significant because there is no cure for late AMD, especially for dry AMD. The management for most of the early and intermediate patients affected consists of antioxidant supplements and risk factors reduction. Anti-VEGF injections are the mainstay treatment for patients with neovascular AMD, which can improve and stabilize vision but can’t cure the disease. In the last decade there have been some technological advancements in what concerns the diagnosis and also the management of the disease, so for patients with AMD there is now more hope than ever in every stage of the disease.
Ranetti et al. (Wed,) studied this question.